

TADA2A RABBIT PAB

货号: S220263

产品全名: TADA2A 兔多抗

基因符号: ADA2; ADA2A; KL04P; hADA2; TADA2L

UNIPROT ID: O75478 (Gene Accession - NP_001159577)

背景: Many DNA-binding transcriptional activator proteins enhance the initiation rate of RNA polymerase II-mediated gene transcription by interacting functionally with the general transcription machinery bound at the basal promoter. Adaptor proteins are usually required for this activation, possibly to acetylate and destabilize nucleosomes, thereby relieving chromatin constraints at the promoter. The protein encoded by this gene is a transcriptional activator adaptor and has been found to be part of the PCAF histone acetylase complex. Several alternatively spliced transcript variants encoding different isoforms of this gene have been described, but the full-length nature of some of these variants has not been determined.

抗原: Synthetic peptide of human TADA2A

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 25-100; ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Epigenetics and Nuclear Signaling


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human cervical cancer tissue using 220263(TADA2A Antibody) at a dilution of 1/25(Nucleus).



In comparison with the IHC on the left, the same paraffin-embedded Human cervical cancer tissue is first treated with the synthetic peptide and then with 220263(Anti-TADA2A Antibody) at dilution 1/25.



The image on the left is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using 220263(Anti-TADA2A Antibody) at a dilution of 1/25.



In comparison with the IHC on the left, the same paraffin-embedded Human ovarian cancer tissue is first treated with synthetic peptide and then with D261229(Anti-TADA2A Antibody) at dilution 1/25.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
